Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.48 |
| ▸ | HTR2B | P41595 | 8/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419084 | 0.83 | SLC6A2 (0.54) | HTR2CHTR2BHTR2AHRH3CHRNB2 | |
| SCHEMBL18452851 | 0.82 | HTR2C (0.68) | HTR2CHTR2BHTR2AHRH3CHRNB2 | |
| SCHEMBL18488412 | 0.82 | HTR2C (0.68) | HTR2CHTR2BHTR2AHRH3CHRNB2 | |
| SCHEMBL38662318 | 0.81 | ADRB2 (0.47) | HTR2CHTR2BHTR2AHRH3CHRNB2 | |
| SCHEMBL25389269 | 0.79 | HTR2C (0.54) | HTR2CHTR2BHTR2AHRH3HTR6 | |
| SCHEMBL25389466 | 0.79 | HTR2C (0.54) | HTR2CHTR2BHTR2AHRH3HTR6 | |
| SCHEMBL2155124 | 0.77 | RAD52 (0.46) | HTR2CHTR2BHTR2AHRH3HTR6 | |
| SCHEMBL17536150 | 0.77 | SLC6A2 (0.48) | HTR2CHTR2BHTR2AHTR6SLC6A2 | |
| SCHEMBL5633055 | 0.77 | RAD52 (0.46) | HTR2CHTR2BHTR2AHRH3HTR6 | |
| SCHEMBL5632812 | 0.77 | RAD52 (0.46) | HTR2CHTR2BHTR2AHRH3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | AQP3, SLC6A7, ABCG2 | HTR2C 491/4885HTR2B 1129/4885HTR2A 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.